MedPlus as reflected by its GMP and amid improved sentiments listed at Rs. 1015 on the BSE. On the NSE, the stock opened at a price of Rs. 1040, a 31 percent premium in comparison to the issue price of Rs. 796 per share.
The market sentiment have comparatively improved as Omicron related worries have eased and the GMP of the stock a day prior to the listing has been Rs. 180 as per ipowatch.in. While as per another publication the GMP has gone down to Rs. 90-100 apiece, a premium of 10-12 percent in comparison to its issue price of Rs. 796. So, the listing price can be likely between Rs. 886-896 per share.
The premium listing anticipated for the issue is owing to strong financial as well as business model.
The issue of Med Plus that ran between December 13-15 saw huge investor interest with bids received about 53 times.
The Rs 1,398 crore IPO consisted of a Rs 600 crore fresh issue and an offer for sale by selling stake of Rs 798.3 crore.